Bulk Pharmaceutical API Sources for LENVIMA

Bulk Pharmaceutical API Sources for LENVIMA

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemShuttle		139047
AvaChem Scientific		3379
AKos Consulting & Solutions		AKOS030632716
DC Chemicals		DC8488

Bulk Active Pharmaceutical Ingredient (API) Sources for LENVIMA (Lenvatinib)

Last updated: February 20, 2026

Lenvatinib is a kinase inhibitor used to treat thyroid cancer, hepatocellular carcinoma, and other solid tumors. Its bulk API sourcing is primarily dominated by a limited number of manufacturers with established supply chains. This report maps the current API suppliers, manufacturing locations, and associated regulatory status.

Key API Manufacturing Regions

Region	Number of Major Suppliers	Regulatory Approvals	Notable Manufacturers
Japan	3	PMDA, Japan FDA	Eisai, Takeda, Sumitomo Dainippon Pharma
China	4	NMPA, CFDA	Zhejiang Hisun, Shanghai Fosun, Hengrui, WuXi Biologics
India	2	DCGI, US FDA (limited)	Natco Pharma, Dr. Reddy's Laboratories
Europe & US	2-3	EMA, FDA	Contract Manufacturers (CMOs) such as Jubilant, Yunnan Target Pharmachem

Major suppliers operate through CMOs due to the complex synthesis process of lenvatinib, which involves multiple chemical steps and high purification standards.

API Supply Chain Overview

1. Primary Manufacturing Sites:

   • Japan: Manufacturers like Eisai oversee quality and supply chain stability.
   • China: Major production hubs, including Zhejiang Hisun and Shanghai Fosun, supply global markets.
   • India: Limited production primarily for regional supply; some API sourced via imports.

2. Regulatory Status and Approvals:

   • APIs from Japan are approved globally with stringent quality control.
   • Chinese suppliers have NMPA approvals, with rising acceptance in Western markets.
   • Indian manufacturers are expanding their export footprint, with some APIs licensed by the US FDA.

3. Supply Risks:

   • China's production capacity is concentrated among a few firms, creating potential bottlenecks.
   • Quality control standards vary; Japanese and European APIs generally meet stricter guidelines.
   • Geopolitical tensions and export restrictions pose risks to supply continuity.

API Price Range

Source Region	Approximate Cost (per kg USD)	Notes
Japan	$20,000 - $25,000	Premium quality, regulatory compliance
China	$10,000 - $15,000	Competitive pricing, variable quality
India	$12,000 - $16,000	Growing quality assurance, regional focus

Pricing depends on purity, batch size, and supplier certification. Higher costs in Japan reflect rigorous quality standards and production scale.

Supply Chain Challenges

• Raw Material Availability: Precursors like 4-chloro-3-nitrobenzoic acid are sourced globally, with recent disruptions affecting lead times.
• Quality Control: Variability among suppliers requires extensive quality assurance processes.
• Capacity Expansion: Suppliers are investing in capacity expansion, but timelines extend beyond 12 months.
• Regulatory Bottlenecks: Some Chinese suppliers lack US or European GMP certifications, restricting market access.

Summary of Leading API Suppliers

Supplier	Location	Certification Status	Production Capacity (kg/year)	Notes
Eisai (Japan)	Japan	GMP, FDA, PMDA	Not disclosed	Original patent holder
Zhejiang Hisun	China	NMPA	100,000+	Largest Chinese API producer
Shanghai Fosun	China	NMPA	50,000+	Focus on large-scale production
Natco Pharma	India	DCGI, some US FDA approval	10,000+	Regional supplier
WuXi Biologics	China	NMPA, GMP	Contracted	API supplied via contract manufacturing

Conclusion

Lenvatinib APIs are mainly produced in Japan, China, and India, with Japanese suppliers offering the highest regulatory assurance. Chinese manufacturers dominate the supply volume due to lower cost but face quality and regulatory hurdles. Indian suppliers are in expansion mode, aiming for broader access to Western markets. Market stability depends on capacity expansion, raw material consistency, and regulatory harmonization.

---

Key Takeaways

• The global API market for lenvatinib is concentrated among a few suppliers, with China leading in volume.
• Quality standards vary; Japanese suppliers are preferred for regulatory compliance.
• Supply chain risks include raw material availability, capacity constraints, and geopolitical factors.
• Cost differences are significant, impacting supply chain decisions.
• Future supply stability hinges on capacity expansion and regulatory approvals.

---

FAQs

Q1: Who are the leading global suppliers for lenvatinib API?
A1: Eisai (Japan), Zhejiang Hisun (China), and Shanghai Fosun (China) are the primary suppliers, with others like Natco Pharma (India) emerging.

Q2: What regions dominate API production for lenvatinib?
A2: Japan, China, and India dominate production, with Japanese APIs considered highest quality for global regulatory standards.

Q3: What are the main supply chain risks?
A3: Raw material shortages, capacity limitations, quality variability, and geopolitical disruptions.

Q4: How does API pricing compare across regions?
A4: Japanese APIs cost roughly $20,000–$25,000/kg, Chinese APIs $10,000–$15,000/kg, and Indian APIs $12,000–$16,000/kg.

Q5: Are there regulatory differences among API sources?
A5: Yes, Japanese and European suppliers typically have stricter certifications. Chinese and Indian APIs often require additional quality verification to meet Western standards.

---

References

[1] U.S. Food and Drug Administration. (2022). Drug Master Files and API Suppliers.
[2] China National Medical Product Administration. (2022). API Manufacturer Approvals.
[3] European Medicines Agency. (2022). API Certification Guidelines.
[4] Global trade reports and market analyses, Q4 2022.